Drugs / retaspimycin
retaspimycin
also known as
IPI 504 · IPI-504 HYDROCHLORIDE · Retaspimicina · Retaspimycin hcl · retaspimycin hydrochloride · Retaspimycine
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT00606814 | Dec 2007 → May 2011 | cancer | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00276302 | Dec 2005 → Nov 2010 | gastrointestinal stromal tumor, soft tissue sarcoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00113204 | Jun 2005 → Mar 2007 | plasma cell myeloma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT01427946 | Jul 2011 → Jun 2014 | non-small cell lung carcinoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00627627 | Apr 2008 → Feb 2010 | breast cancer | MedImmune LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00431015 | Jan 2007 → Aug 2011 | lung cancer | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT01228435 | Oct 2010 → Feb 2012 | lung cancer | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00969917 | Jan → Dec 2010 | dedifferentiated liposarcoma | Infinity Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT00817362 | Mar 2009 → Aug 2010 | HER2 positive breast carcinoma | Infinity Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00627419 | Feb 2008 → Oct 2009 | metastatic melanoma | Infinity Pharmaceuticals, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00564928 | Nov 2007 → Mar 2010 | prostate cancer | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00688766 | Aug 2008 → May 2009 | gastrointestinal stromal tumor | Infinity Pharmaceuticals, Inc. | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01362400 Comparator | May 2011 → Mar 2014 | non-small cell lung carcinoma | Infinity Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | retaspimycin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00688766 ↗ |
| Known as | IPI 504 | “450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 \& 15 during each 21 day cycle” NCT01362400 ↗ |
| Known as | IPI-504 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1184904 ↗ |
| Known as | Retaspimicina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1184904 ↗ |
| Known as | Retaspimycin hcl | ChEMBL registry synonym — accepted as the source's own label CHEMBL1184904 ↗ |
| Known as | retaspimycin hydrochloride | “retaspimycin hydrochloride (IPI-504)” NCT00688766 ↗ |
| Known as | Retaspimycine | ChEMBL registry synonym — accepted as the source's own label CHEMBL1184904 ↗ |
| Action | Inhibit | “Selective inhibition of Hsp90 will affect multiple downstream mechanisms to disrupt tumor growth and selectively kill cancer cells.” NCT00113204 ↗ |
| Modality | Small molecule | “IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90)” NCT00113204 ↗ |
| Route | Intravenous | “IV administration of IPI-504” NCT00276302 ↗ |